We studied the outcome of allo-SCT after reduced-intensity conditioning in relapsed or refractory indolent and aggressive lymphoid malignancies. All 54 patients (diagnosis: B-CLL n ¼ 13, indolent lymphoma n ¼ 12, aggressive lymphoma n ¼ 13, transformed lymphoma n ¼ 16) received conditioning with fludarabine and CY between July 2001 and November 2010. They underwent allo-SCT because of relapse after auto-SCT or because no other therapy could lead to a meaningful remission. Patients received an unmanipulated peripheral blood stem-cell graft. Median follow-up was 67 months. Thirty-two patients had received rituximab. Immediately after transplantation, remission status had improved in 21 patients, all without DLI. During the follow-up six additional patients achieved CR without further therapy. Four-year OS (EFS) was 46% (46%) for B-CLL, 83% (75%) for indolent lymphoma, 69% (55%) for aggressive lymphoma and 74% (67%) for transformed lymphoma (P ¼ 0.28 (P ¼ 0.54)). Forty two percent developed acute GVHD, 68% chronic GVHD (16% limited, 52% extensive). Previous auto-SCT did not influence OS, while acute GVHD did. Two-year non-relapse mortality was 16%. In conclusion, reduced-intensity conditioning with fludarabine-CY is feasible and effective for both indolent and aggressive lymphoid malignancies, even after previous auto-SCT. Because of the excellent anti-B-cell/lymphoma activity fludarabine-CY decreases tumor load, gaining time for the development of a graft versus lymphoma effect.
INTRODUCTION
Allo-SCT is a potentially curative treatment in cases of relapsed lymphoid malignancies. However, myeloablative conditioning is associated with considerable TRM and morbidity, which may be as high as 40-70%. 1, 2 To improve upon these results and to expand accessibility of this procedure to older and less fit patients, reduced-intensity conditioning was introduced. [3] [4] [5] Results were similar or even better as compared with myeloablative conditioning, mainly due to a lower TRM. However, as may be expected, relapse rates were higher than those following myeloablative conditioning. 6, 7 It was also questioned whether reduced-intensity condition would be appropriate for aggressive lymphomas because, due to the kinetics of the disease, these regimens may be less able to control the disease until the graft versus lymphoma can exert its effect. 8 Nevertheless, several small series have been reported, describing the potentially curative potential of reduced-intensity allo-SCT even in aggressive lymphomas. 9, 10 To further assess the role of this treatment modality, we reviewed outcomes of 54 patients with relapsed or refractory indolent as well as aggressive lymphoid malignancies, who received allo-SCT following reduced-intensity conditioning in our center. The conditioning regimen consisted of a combination of fludarabine and CY that, as has been shown in other studies, produced only short-term myelosuppression and demonstrated good engraftment while, because T-cell depletion was not performed, retaining the graft versus lymphoma (GvL) effect. 11 The patient group reported here is heterogeneous with respect to lymphoma type and previous treatments, however, all patients had at least a stable disease at the time of transplantation.
PATIENTS AND METHODS Patients
All patients who received allo-SCT after reduced-intensity conditioning with fludarabine and CY for lymphoid malignancies between July 2001 and November 2010 at the VU University Medical Center were reviewed. Allo-SCT was indicated because of relapse after auto-SCT or because no further therapy was expected to lead to cure or a meaningful remission.
Because only two patients with Hodgkin's lymphoma were transplanted, both were excluded from further analysis. Until 2008, only sibling allo-SCTs were performed. After 2008, unrelated donor transplants were also performed. All donors were fully HLA (high resolution 10/10) matched.
Conditioning regimen and prophylaxis against GVHD
The conditioning regimen consisted of fludarabine 25 mg/m 2 once daily i.v. and CY 500 mg/m 2 once daily i.v., both from day À 7 until À 3. On the day of transplantation (day 0), patients received an unmanipulated PBSC graft, targeting at a minimum of 4.0 Â 10 6 CD34 þ cells/kg body weight of the patient.
GVHD 
End points/objective
The objective of this study was to assess OS and EFS. Secondary end points were relapse rate, non-relapse mortality (NRM) and cumulative incidence of acute and chronic GVHD.
Acute GVHD was rated as occurrence of GVHD within 100 days after allo-SCT, and graded as described by Przepiorka.
12 Chronic GVHD was defined by the revised Seattle criteria, in which chronic GVHD is separated into a limited and extensive form. 13 
Statistical analysis
Data were collected using retrospective chart and database review and were analyzed using the SPSS statistical package (version 20.0, IBM Corporation). OS and EFS were estimated using the Kaplan-Meier method and compared using the log rank test.
OS was calculated as the time between date of allo-SCT and death, or patients were censored at the last follow-up. EFS was calculated as the time between date of allo-SCT and the first relapse or progression or death of any cause.
With the use of univariate analysis (log rank test) the following possible prognostic factors were analyzed: age, diagnosis groups, time from diagnosis until transplant, previous treatments, previous auto-SCT, disease status at the time of transplant, CMV mismatch, ABO mismatch, sex mismatch (donor female, recipient male), acute and/or chronic GVHD, and previous rituximab treatment or not.
RESULTS
A total of 54 patients (median age 53 years, range 36-68) were treated with allo-SCT after conditioning with fludarabine and CY between July 2001 and November 2010. All patients were transplanted with an HLA-compatible sibling except two (one B-CLL, one diffuse large B-cell lymphoma (DLBCL)), who were transplanted with a 10/10-matched unrelated donor.
Median follow-up of all patients was 53 months (range 2-130 months). Median follow-up of all patients alive at the last followup is 67 months (range 19-130 months).
Patients were diagnosed with B-CLL (n ¼ 13), indolent B-cell lymphoma (n ¼ 12), aggressive lymphoma (n ¼ 13) and 16 had DLBCL classified as transformation of indolent lymphoma (previous diagnosis of indolent lymphoma, now diagnosed with DLBCL). For more detailed patient characteristics see Table 1 .
Patients received a median of three lines of therapy before allo-SCT, including re-induction therapy, and 16 patients (29%) had previously been treated with auto-SCT (5 indolent lymphomas, 9 aggressive lymphomas and 2 transformed lymphomas). Median time from autologous to allogeneic transplant was 38 months (range 11-96 months).
In all, 22 patients never received rituximab in the course of their disease, whereas 32 did receive rituximab, mostly in the last year(s) before transplant.
Engraftment, chimerism and DLI All patients achieved complete donor chimerism at 1 year after transplantation, except two, who never achieved remission and eventually progressed. Median time to neutrophil recovery (40.5 Â 10.9/L) was 19 days (range 7-51 days). No early or late graft failures occurred. In nine patients, immune suppression was stopped prematurely at about 2 months post transplant, because of incomplete and/or decreasing donor chimerism. Five patients required DLI during follow-up. One patient received DLI because of persistent B-CLL, despite discontinuing immune suppression at 3 months. Four patients received DLI because of relapse: two of them had indolent lymphoma, one attained persistent CR and the second achieved stable disease for 2 years after DLI. Two patients had transformed lymphomas: one, with a relapse of the indolent component, is now in CR. The other patient relapsed with the aggressive component that remained sensitive to chemotherapy and DLI, although he eventually died of a second aggressive relapse 4 years later. Only the patient who required DLI for mixed donor chimerism developed GVHD afterwards without an Reduced-intensity allo-SCT in lymphoid malignancies MJ Wondergem et al apparent effect on his disease and chimerism status, and was eventually retransplanted from a second donor. He died after this second allo-SCT of acute GVHD. Remission status before and after allo-SCT per patient group is shown in Figure 1 . After transplant, all the patients who were in CR at transplant remained in CR (n ¼ 20). An additional 18 patients who were in PR before allo-SCT, attained CR in the first 3 months after allo-SCT. Three patients with stable disease were in PR immediately after transplant but eventually reached CR and three patients in PR eventually improved to CR, all without DLI. Four patients relapsed within 6 months, and seven relapsed more than 6 months after transplant (range 9-58 months).
Survival
For the entire patient group, 2-year OS was 76% and 4-year OS was 67%, with an EFS of 70% and 66%, respectively (see Figure 2) . During the follow-up period 18 patients died, 6 of disease progression, the others of GVHD and/or infections (Table 1) .
Analysis per disease category revealed a 4-year OS for B-CLL of 46% (95% confidence interval (CI): 19-73%), 83% for indolent B-cell lymphoma (95% CI: 62-100%), 69% for aggressive lymphoma (95% CI: 44-94%) and 74% for transformed lymphoma (95% CI: 52-96%) (NS, P ¼ 0.28, see Figure 3 ).
Four-year EFS was 46%, 75%, 55% and 67%, respectively (95% CI: 19-73%, 51-100%, 24-87% and 44-91%, respectively, NS, P ¼ 0.54).
OS was not significantly different between patients with (n ¼ 16) or without (n ¼ 38) previous auto-SCT (Figure 4) .
Patients who were in CR before allo-SCT had better 4-year OS than patients who were not (77% versus 63%), the difference, however, being not statistically significant (P ¼ 0.47) ( Figure 5 ).
Survival or remission status at transplant was not different between the patients who had or had not received rituximab at any time during their treatment (CR 36% and PR 54% without rituximab versus 34% and 59% with rituximab, respectively).
Patients with only acute GVHD had significantly shorter OS (P ¼ 0.003), whereas those with acute GVHD and who subsequently developed chronic GVHD did better with similar OS as the patients with only chronic GVHD or no GVHD ( Figure 6 ).
Prognostic factors for survival Univariate analysis, with the use of a log rank test, identified few variables having prognostic significance for OS. Table 2 shows all possible variables with their corresponding P-values. Only acute GVHD was significantly (P ¼ 0.046) predictive for worse survival; however, this is based on only six patients ( Figure 6) .
One-year NRM was 11%, increasing to 16% after 2 years, without any difference between indolent and aggressive lymphoma (95% CI: 2.2-20% and 5.7-26%, respectively).
Four patients died of infectious diseases, of whom three patients used high-dose prednisone to treat GVHD. GVHD Twenty-three patients (42%) developed acute GVHD after transplantation, of which 7 patients had grade I acute GVHD and 16 patients grade II-IV. In all, 14 patients developed acute GVHD before discontinuation of immune suppression, 7 needed systemic steroids and 7 could be managed with topical steroids only (the latter having grade I acute GVHD of the skin). Nine patients developed acute GVHD after discontinuation of immune supression: four after discontinuation of MMF (1-3 weeks after stopping) and 5 after discontinuation of CYA (2-6 weeks, median Reduced-intensity allo-SCT in lymphoid malignancies MJ Wondergem et al 3 weeks). All needed systemic GVHD therapy. Four-year OS was 72% in the group with grade I acute GVHD, and 42% in the group with grade II-IV acute GVHD needing systemic steroids (P ¼ 0.13).
Overall, 34 patients (68% of evaluable patients) developed chronic GVHD, of which 8 (16%) had limited and 26 (52%) had extensive disease. Two patients developed chronic GVHD before discontinuation of immune suppression and four during reduction of CYA. Twenty-two patients developed chronic GVHD after discontinuation of CYA (median 6 weeks (1-40 weeks) after stopping). Seventeen patients had also experienced acute GVHD. Seven patients eventually died because of GVHD (two due to liver GVHD, two of bronchiolitis obliterans syndrome and three of gastrointestinal GVHD). At 1 year post transplant, 45 patients were evaluable, 23 with chronic GVHD. At the last follow-up, with a median follow-up of 6 years, 13 patients of the 36 patients alive (of whom 25 had suffered from acute and/or chronic GVHD) were still being treated for chronic GVHD.
DISCUSSION
In this large cohort of homogeneously treated patients with relapsed or refractory B-cell malignancies, with a mean follow-up of more than 4 years, allo-SCT after reduced-intensity conditioning with fludarabine and CY proved to be an effective therapy leading to excellent long-term survival with acceptable toxicity.
These encouraging survival data may, at least partly, be explained by the fact that only patients with chemosensitive disease were transplanted. Chemoresistance is a known predictor of poor outcome after reduced-intensity conditioning. 14, 15 Second, the use of fludarabine-CY as a conditioning regimen is effective, as reflected by the evident improvement of remission status in 39% of the patients in the first 3 months after transplantation while they were still on immunosuppressive therapy. This is important in view of the delayed GVL following allo-SCT.
NRM was acceptable with 11% at 1 year and 16% at 2 years, without a difference between indolent and aggressive lymphomas. This compares favorably with previously published reports in this patient group. For example: Rezvani et al. reported a 3-year NRM for both indolent and aggressive lymphomas of 23% after fludarabine-TBI conditioning. Rodriguez et al.
6,10 found 28% 2-year NRM for the same patient group after fludarabinemelphalan. Morris et al. 16 reported a 3-year NRM of 11% for indolent lymphomas and 38% for aggressive lymphomas after fludarabine-melphalan-alemtuzumab conditioning. Although the number of treatment lines received did not affect survival in our analysis, more intensive pretreatment may have negatively affected NRM in the reported series.
In this analysis, survival of 46% at 4 years for CLL patients appeared to be worse as compared with other malignancies. In contrast, in the series of Sorror et al., 17 CLL patients did not perform worse than the aggressive lymphomas. However, Corradini et al. 5 found in a sub-analysis on the follicular lymphoma and CLL patients that OS was significantly worse for Reduced-intensity allo-SCT in lymphoid malignancies MJ Wondergem et al CLL patients (3-year OS 53% versus 88%), mainly due to a higher relapse risk (3-year relapse risk 46% versus 14%). This was not seen in our patients, where NRM was the main cause of death (only one relapse in seven patients that died, see Table 1 ).
Patients with indolent lymphoma experienced the best 4-year OS of 83%. Khouri et al. 3 reported similar survival rates of 84% at 2 years in his group of follicular lymphomas and small lymphocytic lymphoma after conditioning with fludarabine and CY.
Conflicting data exist as to whether indolent versus aggressive histology impacts upon results after reduced-intensity regimens for allo-SCT. In our series, there was no significant difference in the outcome between both groups. Corradini et al. 5 found a similar survival for his indolent and aggressive lymphomas (3-year OS 69%). However, in the series of Armand et al., 18 indolent histology indeed was a predictor of better OS with 81% as opposed to 42% in the aggressive lymphomas. We suggest that reduced-intensity allo-SCT should be considered in cases of relapsed or refractory aggressive lymphomas as significant long-term survival can be achieved, especially in chemosensitive diseases.
Survival was not affected by a previous auto-SCT in this analysis, which was also seen in several other series of reduced-intensity allo-SCT. 19 However, Rodriguez et al. 6 found a significantly worse OS after allo-SCT with reduced-intensity conditioning when patients had been treated with auto-SCT before. Rezvani reports that patients treated with auto-SCT immediately before allo-SCT did worse. However, this seems to be explained by the fact that this tandem approach was performed because of their very resistant disease. 10 Others found that patients with a short time difference from auto-SCT to allo-SCT have a higher NRM and lower PFS. 20 We included only chemosensitive patients, and the interval between auto-SCT and allo-SCT was quite long (range 11-96 months, median 38 months). These two facts might be related as patients relapsing shortly after auto-SCT often are more refractory to salvage treatment. Our data indicate that if patients respond well to the salvage treatment, previous auto-SCT is not a negative predictor for survival when the interval between transplants is a year or more.
Auto-SCT of DLBCL patients at first relapse, with a cure rate of around 50% in reported series, is still considered first choice for this patient catergory. 21 Auto-SCT has the benefit of lacking the risk of GVHD, an important cause of morbidity and mortality after allogeneic transplantation, with major impact on the quality of life. 22 However, all relapses in the current era occur after previous treatment with rituximab and these patients seem to be more resistant to salvage therapy. 23 To avoid increased NRM when allo-SCT is performed shortly after auto-SCT, up-front allo-SCT for this specific patient group may be a valid option. This should preferably be tested in a prospective study, also taking quality of life into consideration.
Our observation that previous treatment with rituximab during the remission induction does not add to survival or remission status is most likely explained by the fact that we performed transplantation in patients with chemosensitive diseases. It suggests that having responsive disease is more important than the kind of treatment used to achieve that response.
Studies by the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation (EBMT) have reported that allo-SCT leads to a significantly lower risk of relapse compared with auto-SCT, which may relate to the GVL effect. 1, [24] [25] [26] In our relapsed patients, DLI could be performed in five patients and induce permanent or temporary remissions in four of them. This, and the six additional patients improving their remission after transplant, reaching CR without further therapies, supports the existence of the GVL effect. Moreover, chronic GVHD decreases relapse rate, which can also be attributed to a GVL effect. 27 All six patients who experienced improvement of their remission status in the year after transplant suffered from chronic GVHD.
The incidence of acute GVHD (42%) and chronic GVHD (68%) in our patients is similar to the reported series of non-T-cell-depleted reduced-intensity regimens. 3, 6, 10 We found that acute GVHD negatively affected survival ( Figure 6 ). Although not significant, OS seemed worse in patients with grade II-IV acute GVHD versus grade I GVHD (42% versus 72%, P ¼ 0.12). The shorter survival might be explained by the need for systemic steroids early after transplant in more severe acute GVHD with additional risks of severe infections, which indeed occurred in three patients. Van Kampen et al. 20 reported similar higher NRM in patients with acute GVHD.
The group of patients with long-term persistent chronic GVHD in our series was 24% of all patients undergoing allo-SCT. Most studies on allo-SCT report incidence and not long-term persistence of GVHD. Analyses of quality of life focus more on long-term morbidity and show similar percentages of chronically impaired survivors, GVHD having a robust negative relationship with quality of life. 22 The incidence of GVHD, both acute and chronic, is lower when transplantation is performed after T-cell depletion, the benefit on survival usually being offset by more infections and a higher relapse rate through abrogation of the GVL effect. Robinson et al.
14 reported 29% acute GVHD after T-cell depletion with either ATG or alemtuzumab versus 58% in recipients of non-T-celldepleted grafts. Morris et al. 16 reported 30% acute GVHD and 6.8% chronic GVHD after alemtuzumab-containing reduced-intensity conditioning. Eventual 3-year OS was only 35% for high-grade lymphoma (8/37 refractory disease) and 73% for low-grade lymphoma (1/41 refractory). It could be argued whether the increased risk of relapse is counterbalanced by the gain of less toxicity.
In conclusion, reduced-intensity conditioning with fludarabine-CY is a feasible scheme with acceptable toxicity and proven longterm efficacy. It is effective for both indolent and aggressive lymphoid malignancies, even after previous auto-SCT, provided patients are sensitive to re-induction therapy. Because of the excellent anti-lymphoma activity, the fludarabine-CY regimen deepens responses after allo-SCT, allowing time for the development of a GVL effect.
